YieldMax TSLA Option Income Strategy ETF vs GeneDx Holdings Corp — how do they compare? YieldMax TSLA Option Income Strategy ETF trades at $21.65, while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| TSLY | WGS | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $48.25 | $167.51 |
52-Week Low | $20.49 | $34.51 |
Market Cap | — | $2.44B |
Enterprise Value | — | $2.48B |
Signals from Pluang's Aura AI — not financial advice
TSLY trades at $21.57, down 0.74% today, with a bearish technical outlook indicated by moving averages and key indicators. The ETF generates substantial income through weekly distributions, with recent dividends ranging from $0.23 to $0.52 per share. However, the structure caps upside potential during Tesla rallies, as noted in recent analyst commentary.
While TSLY offers high yield potential through its option income strategy, investors face significant risks including capped upside capture, volatility exposure from Tesla's underlying performance, and potential return of capital distributions. The neutral sentiment from oscillators suggests limited near-term directional momentum.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Trailing returns across standard periods
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →